Product Information
ATROVENT 17 MCG HFA INHALER is a brand product labeled by Boehringer Ingelheim Pharmaceuticals Inc., priced at $22.7630 per GM under NDC 00597008717. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on Nov 27, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the ipratropium bromide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
17 ug/1
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc.NDC
00597008717
Classification
Brand
Dosage Form
AEROSOL, METERED
Route
RESPIRATORY (INHALATION)
Effective Date
8/19/2026
Active Ingredients
IPRATROPIUM BROMIDEApproval Type
New Drug (NDA)
FDA Application
NDA021527FDA Approved
11/27/2004
TE Code
AB
On Market Since
5/1/2005
Pharmacological Classes
Price Statistics
The NADAC for ATROVENT 17 MCG HFA INHALER has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 39.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $22.7630 per GM |
|---|---|
| All-time high | $35.1533 (Jun 12, 2024) |
| All-time low | $16.2887 (Nov 28, 2013) |
| 52-week high | $22.7976 |
| 52-week low | $22.7630 |
| Median price | $26.7426 |
| Average price | $26.9626 |
| Largest weekly change | -35.0% (Jan 8, 2025) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ipratropium bromide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ATROVENT 17 MCG HFA INHALER?
The current National Average Drug Acquisition Cost (NADAC) for ATROVENT 17 MCG HFA INHALER, manufactured by Boehringer Ingelheim Pharmaceuticals Inc., is $22.7630 per GM (NDC 00597008717), effective Aug 19, 2026.
How has the price of ATROVENT 17 MCG HFA INHALER changed over time?
Over the history we have for it, the NADAC for ATROVENT 17 MCG HFA INHALER has risen 39.7%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ATROVENT 17 MCG HFA INHALER?
Since Nov 28, 2013, the NADAC for ATROVENT 17 MCG HFA INHALER has ranged from a low of $16.2887 (Nov 28, 2013) to a high of $35.1533 (Jun 12, 2024), with a median of $26.7426 per GM.
Are there cheaper alternatives to ATROVENT 17 MCG HFA INHALER?
No other NADAC-published product currently shares the active ingredient and strength of ATROVENT 17 MCG HFA INHALER in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ATROVENT 17 MCG HFA INHALER?
ATROVENT 17 MCG HFA INHALER (NDC 00597008717) is labeled by Boehringer Ingelheim Pharmaceuticals Inc., and CMS classifies it as a brand product.